demonstrated a susceptibility of LKB1-null NSCLC cell lines to RNAi-mediated signaling of SRC and FAK and the ability of the SRC inhibitor Dasatinib or the FAK inhibitor PF 573228 to reduce cell adhesion and migration (129, 154). This evidence concerns the gene STK11 and non-small cell lung carcinoma.